Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001313735 | SCV001504239 | uncertain significance | not provided | 2022-03-10 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 1779 of the CDH23 protein (p.Val1779Leu). This variant is present in population databases (rs376114326, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with CDH23-related conditions. ClinVar contains an entry for this variant (Variation ID: 1014931). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C25"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003355380 | SCV004078373 | uncertain significance | Inborn genetic diseases | 2023-06-21 | criteria provided, single submitter | clinical testing | The c.5335G>C (p.V1779L) alteration is located in exon 41 (coding exon 40) of the CDH23 gene. This alteration results from a G to C substitution at nucleotide position 5335, causing the valine (V) at amino acid position 1779 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001835547 | SCV002089408 | uncertain significance | Usher syndrome type 1 | 2021-02-02 | no assertion criteria provided | clinical testing |